| Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia. | |
| | |
MedLine Citation:
|
PMID: 2180267 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A variety of double-blind studies have compared the efficacy of hydroxymethylglutaryl coenzyme A reductase inhibitors (lovastatin and simvastatin) with that of control agents (cholestyramine, fibrates and probucol) in patients with type IIA or IIB primary hypercholesterolemia. Results have shown that both lovastatin and simvastatin are more effective than the standard therapies with regard to reducing total and low-density lipoprotein cholesterol. Decreases in triglycerides and increases in high-density lipoprotein cholesterol were generally greater with fibrates. Ongoing studies are assessing the benefits of lovastatin and simvastatin in reducing the incidence of mortality from coronary artery disease, as well as causing regression of coronary atheroma. |
| | |
Authors:
|
J F Walker; D R Shapiro |
Related Documents
:
|
18333357 - Apolipoproteins a-i and b-markers in coronary risk evaluation. 9400857 - Discrimination of metabolite from lipid and macromolecule resonances in cerebral infarc... 17399827 - Current questions regarding the use of statins in patients with coronary heart disease. 7301687 - Myocardial infarction in familial hyper-alpha and hypo-beta-lipoproteinaemia. 3119687 - Effect of calcium-binding additives on ventricular fibrillation and repolarization chan... 21206197 - The frequency of silent myocardial ischemia associated with femoral sheath removal and ... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: The American journal of cardiology Volume: 65 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 1990 Mar |
Date Detail:
|
Created Date: 1990-04-19 Completed Date: 1990-04-19 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 19F-22F Citation Subset: AIM; IM |
Affiliation:
|
Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bezafibrate
/
therapeutic use Cholestyramine Resin / therapeutic use Double-Blind Method Gemfibrozil / therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors* Hypercholesterolemia / blood, drug therapy* Lipids / blood Lovastatin / analogs & derivatives, therapeutic use Probucol / therapeutic use Randomized Controlled Trials as Topic Simvastatin |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 11041-12-6/Cholestyramine Resin; 23288-49-5/Probucol; 25812-30-0/Gemfibrozil; 41859-67-0/Bezafibrate; 75330-75-5/Lovastatin; 79902-63-9/Simvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: At what levels of total low- or high-density lipoprotein cholesterol should diet/drug therapy be ini...
Next Document: Clinical experience with lovastatin.